Skip to content
10-Q

Quarterly Report

Seelos Therapeutics, Inc.

0001410578-24-000773

← back to feed
Filed
May 14, 2024 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2024 · May 8, 2024 17.38M sh
Shares Diluted Q1 2024 · Mar 31, 2024 13.01M sh
Shares Diluted restated Q1 2024 · Mar 31, 2023 3.75M sh
Operating Cash Flow Q1 2024 · Mar 31, 2024 −$4.64M
Operating Cash Flow Q1 2024 · Mar 31, 2023 −$10.35M
Long Term Debt Q1 2024 · Mar 31, 2024 $13.1M
Stockholders Equity Q1 2024 · Mar 31, 2024 −$33.1M
Stockholders Equity Q1 2024 · Dec 31, 2023 −$33.51M
Stockholders Equity Q1 2024 · Mar 31, 2023 −$20.66M
Stockholders Equity Q1 2024 · Dec 31, 2022 −$10.61M
Current Liabilities Q1 2024 · Mar 31, 2024 $36.72M
Current Liabilities Q1 2024 · Dec 31, 2023 $38.93M
Total Liabilities Q1 2024 · Mar 31, 2024 $36.72M
Total Liabilities Q1 2024 · Dec 31, 2023 $38.93M
Current Assets Q1 2024 · Mar 31, 2024 $3.55M
Current Assets Q1 2024 · Dec 31, 2023 $5.4M
Total Assets Q1 2024 · Mar 31, 2024 $3.61M
Total Assets Q1 2024 · Dec 31, 2023 $5.42M
Eps Diluted Q1 2024 · Mar 31, 2024 −$0.20
Eps Diluted restated Q1 2024 · Mar 31, 2023 −$3.58
Eps Basic Q1 2024 · Mar 31, 2024 −$0.20
Eps Basic restated Q1 2024 · Mar 31, 2023 −$3.58
Rd Expense Q1 2024 · Mar 31, 2024 $3.53M
Rd Expense Q1 2024 · Mar 31, 2023 $5.67M
Net Income Q1 2024 · Mar 31, 2024 −$2.66M
Net Income Q1 2024 · Mar 31, 2023 −$13.43M
Operating Income Q1 2024 · Mar 31, 2024 −$6.06M
Operating Income Q1 2024 · Mar 31, 2023 −$8.93M
Revenue Q1 2024 · Mar 31, 2024 $579K
Revenue Q1 2024 · Mar 31, 2023 $808K
Stock Repurchased Q1 2024 · Mar 31, 2023 $1.2M